Selected research
Industry Growth & Trends
Global Rare Disease Pharmaceutical Service Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Rare Disease Pharmaceutical Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Rare Disease Pharmaceutical Service is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Rare Disease Pharmaceutical Service is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Rare Disease Pharmaceutical Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Rare Disease Pharmaceutical Service market include Ultragenyx, Chiesi, Sciensus, Abbvie, Orpharma, Amgen, Recordati, Novartis and Celgene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Rare Disease Pharmaceutical Service market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Rare Disease Pharmaceutical Service market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Rare Disease Pharmaceutical Service market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Rare Disease Pharmaceutical Service.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Rare Disease Pharmaceutical Service market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Rare Disease Pharmaceutical Service Market by Company
Ultragenyx
Chiesi
Sciensus
Abbvie
Orpharma
Amgen
Recordati
Novartis
Celgene
Amryt Pharma
Johnson & Johnson
GSK
Shire
Merck
Pfizer
Biogen
Sanofi
AstraZeneca
Takeda
Rare Disease Pharmaceutical Service Segment by Type
Drug Discovery
Clinical Trials
Others
Rare Disease Pharmaceutical Service Segment by Application
Congenital and Genetic Diseases
Tumors and Cancer
Endocrine Diseases
Others
Rare Disease Pharmaceutical Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rare Disease Pharmaceutical Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rare Disease Pharmaceutical Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rare Disease Pharmaceutical Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Rare Disease Pharmaceutical Service companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
List of Tables
Table 1. Global Rare Disease Pharmaceutical Service Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032
Table 2. Global Rare Disease Pharmaceutical Service Market Size by Region (2021-2026) & (US$ Million)
Table 3. Global Rare Disease Pharmaceutical Service Market Share by Region (2021-2026)
Table 4. Global Rare Disease Pharmaceutical Service Market Size by Region (2027-2032) & (US$ Million)
Table 5. Global Rare Disease Pharmaceutical Service Market Share by Region (2027-2032)
Table 6. Global Rare Disease Pharmaceutical Service Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 7. Global Rare Disease Pharmaceutical Service Market Size by Type (2021-2026) & (US$ Million)
Table 8. Global Rare Disease Pharmaceutical Service Market Size Share by Type (2021-2026)
Table 9. Global Rare Disease Pharmaceutical Service Market Size Forecasted by Type (2027-2032) & (US$ Million)
Table 10. Global Rare Disease Pharmaceutical Service Market Size Share Forecasted by Type (2027-2032)
Table 11. North America Rare Disease Pharmaceutical Service Market Size Breakdown by Type (2021-2026) & (US$ Million)
Table 12. North America Rare Disease Pharmaceutical Service Market Size Breakdown by Type (2027-2032) & (US$ Million)
Table 13. Europe Rare Disease Pharmaceutical Service Market Size Breakdown by Type (2021-2026) & (US$ Million)
Table 14. Europe Rare Disease Pharmaceutical Service Market Size Breakdown by Type (2027-2032) & (US$ Million)
Table 15. Asia-Pacific Rare Disease Pharmaceutical Service Market Size Breakdown by Type (2021-2026) & (US$ Million)
Table 16. Asia-Pacific Rare Disease Pharmaceutical Service Market Size Breakdown by Type (2027-2032) & (US$ Million)
Table 17. Latin America Rare Disease Pharmaceutical Service Market Size Breakdown by Type (2021-2026) & (US$ Million)
Table 18. Latin America Rare Disease Pharmaceutical Service Market Size Breakdown by Type (2027-2032) & (US$ Million)
Table 19. Middle East and Africa Rare Disease Pharmaceutical Service Market Size Breakdown by Type (2021-2026) & (US$ Million)
Table 20. Middle East and Africa Rare Disease Pharmaceutical Service Market Size Breakdown by Type (2027-2032) & (US$ Million)
Table 21. Global Rare Disease Pharmaceutical Service Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 22. Global Rare Disease Pharmaceutical Service Market Size by Application (2021-2026) & (US$ Million)
Table 23. Global Rare Disease Pharmaceutical Service Market Size Share by Application (2021-2026)
Table 24. Global Rare Disease Pharmaceutical Service Market Size Forecasted by Application (2027-2032) & (US$ Million)
Table 25. Global Rare Disease Pharmaceutical Service Market Size Share Forecasted by Application (2027-2032)
Table 26. North America Rare Disease Pharmaceutical Service Market Size Breakdown by Application (2021-2026) & (US$ Million)
Table 27. North America Rare Disease Pharmaceutical Service Market Size Breakdown by Application (2027-2032) & (US$ Million)
Table 28. Europe Rare Disease Pharmaceutical Service Market Size Breakdown by Application (2021-2026) & (US$ Million)
Table 29. Europe Rare Disease Pharmaceutical Service Market Size Breakdown by Application (2027-2032) & (US$ Million)
Table 30. Asia-Pacific Rare Disease Pharmaceutical Service Market Size Breakdown by Application (2021-2026) & (US$ Million)
Table 31. Asia-Pacific Rare Disease Pharmaceutical Service Market Size Breakdown by Application (2027-2032) & (US$ Million)
Table 32. Latin America Rare Disease Pharmaceutical Service Market Size Breakdown by Application (2021-2026) & (US$ Million)
Table 33. Latin America Rare Disease Pharmaceutical Service Market Size Breakdown by Application (2027-2032) & (US$ Million)
Table 34. Middle East and Africa Rare Disease Pharmaceutical Service Market Size Breakdown by Application (2021-2026) & (US$ Million)
Table 35. Middle East and Africa Rare Disease Pharmaceutical Service Market Size Breakdown by Application (2027-2032) & (US$ Million)
Table 36. Rare Disease Pharmaceutical Service Industry Trends
Table 37. Rare Disease Pharmaceutical Service Industry Drivers
Table 38. Rare Disease Pharmaceutical Service Industry Opportunities and Challenges
Table 39. Rare Disease Pharmaceutical Service Industry Restraints
Table 40. Global Rare Disease Pharmaceutical Service Revenue by Company (US$ Million) & (2021-2026)
Table 41. Global Rare Disease Pharmaceutical Service Revenue Market Share by Company (2021-2026)
Table 42. Global Rare Disease Pharmaceutical Service Industry Company Ranking, 2024 VS 2025 VS 2026
Table 43. Global Rare Disease Pharmaceutical Service Key Company Headquarters & Area Served
Table 44. Global Rare Disease Pharmaceutical Service Company, Product Type & Application
Table 45. Global Rare Disease Pharmaceutical Service Company Commercialization Time
Table 46. Global Company Market Concentration Ratio (CR5 and HHI)
Table 47. Global Rare Disease Pharmaceutical Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 48. Ultragenyx Company Information
Table 49. Ultragenyx Business Overview
Table 50. Ultragenyx Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 51. Ultragenyx Rare Disease Pharmaceutical Service Product Portfolio
Table 52. Ultragenyx Recent Development
Table 53. Chiesi Company Information
Table 54. Chiesi Business Overview
Table 55. Chiesi Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 56. Chiesi Rare Disease Pharmaceutical Service Product Portfolio
Table 57. Chiesi Recent Development
Table 58. Sciensus Company Information
Table 59. Sciensus Business Overview
Table 60. Sciensus Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 61. Sciensus Rare Disease Pharmaceutical Service Product Portfolio
Table 62. Sciensus Recent Development
Table 63. Abbvie Company Information
Table 64. Abbvie Business Overview
Table 65. Abbvie Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 66. Abbvie Rare Disease Pharmaceutical Service Product Portfolio
Table 67. Abbvie Recent Development
Table 68. Orpharma Company Information
Table 69. Orpharma Business Overview
Table 70. Orpharma Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 71. Orpharma Rare Disease Pharmaceutical Service Product Portfolio
Table 72. Orpharma Recent Development
Table 73. Amgen Company Information
Table 74. Amgen Business Overview
Table 75. Amgen Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 76. Amgen Rare Disease Pharmaceutical Service Product Portfolio
Table 77. Amgen Recent Development
Table 78. Recordati Company Information
Table 79. Recordati Business Overview
Table 80. Recordati Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 81. Recordati Rare Disease Pharmaceutical Service Product Portfolio
Table 82. Recordati Recent Development
Table 83. Novartis Company Information
Table 84. Novartis Business Overview
Table 85. Novartis Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 86. Novartis Rare Disease Pharmaceutical Service Product Portfolio
Table 87. Novartis Recent Development
Table 88. Celgene Company Information
Table 89. Celgene Business Overview
Table 90. Celgene Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 91. Celgene Rare Disease Pharmaceutical Service Product Portfolio
Table 92. Celgene Recent Development
Table 93. Amryt Pharma Company Information
Table 94. Amryt Pharma Business Overview
Table 95. Amryt Pharma Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 96. Amryt Pharma Rare Disease Pharmaceutical Service Product Portfolio
Table 97. Amryt Pharma Recent Development
Table 98. Johnson & Johnson Company Information
Table 99. Johnson & Johnson Business Overview
Table 100. Johnson & Johnson Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 101. Johnson & Johnson Rare Disease Pharmaceutical Service Product Portfolio
Table 102. Johnson & Johnson Recent Development
Table 103. GSK Company Information
Table 104. GSK Business Overview
Table 105. GSK Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 106. GSK Rare Disease Pharmaceutical Service Product Portfolio
Table 107. GSK Recent Development
Table 108. Shire Company Information
Table 109. Shire Business Overview
Table 110. Shire Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 111. Shire Rare Disease Pharmaceutical Service Product Portfolio
Table 112. Shire Recent Development
Table 113. Merck Company Information
Table 114. Merck Business Overview
Table 115. Merck Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 116. Merck Rare Disease Pharmaceutical Service Product Portfolio
Table 117. Merck Recent Development
Table 118. Pfizer Company Information
Table 119. Pfizer Business Overview
Table 120. Pfizer Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 121. Pfizer Rare Disease Pharmaceutical Service Product Portfolio
Table 122. Pfizer Recent Development
Table 123. Biogen Company Information
Table 124. Biogen Business Overview
Table 125. Biogen Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 126. Biogen Rare Disease Pharmaceutical Service Product Portfolio
Table 127. Biogen Recent Development
Table 128. Sanofi Company Information
Table 129. Sanofi Business Overview
Table 130. Sanofi Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 131. Sanofi Rare Disease Pharmaceutical Service Product Portfolio
Table 132. Sanofi Recent Development
Table 133. AstraZeneca Company Information
Table 134. AstraZeneca Business Overview
Table 135. AstraZeneca Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 136. AstraZeneca Rare Disease Pharmaceutical Service Product Portfolio
Table 137. AstraZeneca Recent Development
Table 138. Takeda Company Information
Table 139. Takeda Business Overview
Table 140. Takeda Rare Disease Pharmaceutical Service Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026)
Table 141. Takeda Rare Disease Pharmaceutical Service Product Portfolio
Table 142. Takeda Recent Development
Table 143. North America Rare Disease Pharmaceutical Service Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032
Table 144. North America Rare Disease Pharmaceutical Service Market Size by Country (2021-2026) & (US$ Million)
Table 145. North America Rare Disease Pharmaceutical Service Market Share by Country (2021-2026)
Table 146. North America Rare Disease Pharmaceutical Service Market Size Forecast by Country (2027-2032) & (US$ Million)
Table 147. North America Rare Disease Pharmaceutical Service Market Share Forecast by Country (2027-2032)
Table 148. Europe Rare Disease Pharmaceutical Service Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032
Table 149. Europe Rare Disease Pharmaceutical Service Market Size by Country (2021-2026) & (US$ Million)
Table 150. Europe Rare Disease Pharmaceutical Service Market Share by Country (2021-2026)
Table 151. Europe Rare Disease Pharmaceutical Service Market Size Forecast by Country (2027-2032) & (US$ Million)
Table 152. Europe Rare Disease Pharmaceutical Service Market Share Forecast by Country (2027-2032)
Table 153. Asia-Pacific Rare Disease Pharmaceutical Service Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032
Table 154. Asia-Pacific Rare Disease Pharmaceutical Service Market Size by Country (2021-2026) & (US$ Million)
Table 155. Asia-Pacific Rare Disease Pharmaceutical Service Market Share by Country (2021-2026)
Table 156. Asia-Pacific Rare Disease Pharmaceutical Service Market Size Forecast by Country (2027-2032) & (US$ Million)
Table 157. Asia-Pacific Rare Disease Pharmaceutical Service Market Share Forecast by Country (2027-2032)
Table 158. Latin America Rare Disease Pharmaceutical Service Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032
Table 159. Latin America Rare Disease Pharmaceutical Service Market Size by Country (2021-2026) & (US$ Million)
Table 160. Latin America Rare Disease Pharmaceutical Service Market Share by Country (2021-2026)
Table 161. Latin America Rare Disease Pharmaceutical Service Market Size Forecast by Country (2027-2032) & (US$ Million)
Table 162. Latin America Rare Disease Pharmaceutical Service Market Share Forecast by Country (2027-2032)
Table 163. Middle East & Africa Rare Disease Pharmaceutical Service Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032
Table 164. Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Country (2021-2026) & (US$ Million)
Table 165. Middle East & Africa Rare Disease Pharmaceutical Service Market Share by Country (2021-2026)
Table 166. Middle East & Africa Rare Disease Pharmaceutical Service Market Size Forecast by Country (2027-2032) & (US$ Million)
Table 167. Middle East & Africa Rare Disease Pharmaceutical Service Market Share Forecast by Country (2027-2032)
Table 168. Research Programs/Design for This Report
Table 169. Authors List of This Report
Table 170. Secondary Sources
List of Figures
Figure 1.List of Figures
Figure 2. Rare Disease Pharmaceutical Service Product Image
Figure 3. Global Rare Disease Pharmaceutical Service Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 4. Global Rare Disease Pharmaceutical Service Market Size (2021-2032) & (US$ Million)
Figure 5. Global Rare Disease Pharmaceutical Service Market Share by Region: 2025 VS 2032
Figure 6. Global Rare Disease Pharmaceutical Service Market Share by Region (2021-2032)
Figure 7. North America Rare Disease Pharmaceutical Service Market Size Growth Rate (2021-2032) & (US$ Million)
Figure 8. Europe Rare Disease Pharmaceutical Service Market Size Growth Rate (2021-2032) & (US$ Million)
Figure 9. Asia-Pacific Rare Disease Pharmaceutical Service Market Size Growth Rate (2021-2032) & (US$ Million)
Figure 10. Latin America Rare Disease Pharmaceutical Service Market Size Growth Rate (2021-2032) & (US$ Million)
Figure 11. Middle East & Africa Rare Disease Pharmaceutical Service Market Size Growth Rate (2021-2032) & (US$ Million)
Figure 12. Drug Discovery Image
Figure 13. Global Drug Discovery Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 14. Clinical Trials Image
Figure 15. Global Clinical Trials Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 16. Others Image
Figure 17. Global Others Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 18. Global Rare Disease Pharmaceutical Service Market Size Overview by Type (2021-2032) & (US$ Million)
Figure 19. Global Rare Disease Pharmaceutical Service Market Share by Type 2025 VS 2032
Figure 20. North America Rare Disease Pharmaceutical Service Market Size Share by Type (2021-2032)
Figure 21. Europe Rare Disease Pharmaceutical Service Market Size Share by Type (2021-2032)
Figure 22. Asia-Pacific Rare Disease Pharmaceutical Service Market Size Share by Type (2021-2032)
Figure 23. Latin America Rare Disease Pharmaceutical Service Market Size Share by Type (2021-2032)
Figure 24. Middle East and Africa Rare Disease Pharmaceutical Service Market Size Share by Type (2021-2032)
Figure 25. Congenital and Genetic Diseases Image
Figure 26. Global Congenital and Genetic Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 27. Tumors and Cancer Image
Figure 28. Global Tumors and Cancer Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 29. Endocrine Diseases Image
Figure 30. Global Endocrine Diseases Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 31. Others Image
Figure 32. Global Others Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 33. Global Rare Disease Pharmaceutical Service Market Size Overview by Application (2021-2032) & (US$ Million)
Figure 34. Global Rare Disease Pharmaceutical Service Market Share by Application 2025 VS 2032
Figure 35. North America Rare Disease Pharmaceutical Service Market Size Share by Application (2021-2032)
Figure 36. Europe Rare Disease Pharmaceutical Service Market Size Share by Application (2021-2032)
Figure 37. Asia-Pacific Rare Disease Pharmaceutical Service Market Size Share by Application (2021-2032)
Figure 38. Latin America Rare Disease Pharmaceutical Service Market Size Share by Application (2021-2032)
Figure 39. Middle East and Africa Rare Disease Pharmaceutical Service Market Size Share by Application (2021-2032)
Figure 40. Global Top 5 and 10 Rare Disease Pharmaceutical Service Players Market Share by Revenue in 2025
Figure 41. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 42. North America Rare Disease Pharmaceutical Service Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million)
Figure 43. North America Rare Disease Pharmaceutical Service Market Share by Country: 2021 VS 2025 VS 2032
Figure 44. North America Rare Disease Pharmaceutical Service Market Share by Country (2021-2032)
Figure 45. Europe Rare Disease Pharmaceutical Service Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million)
Figure 46. Europe Rare Disease Pharmaceutical Service Market Share by Country: 2021 VS 2025 VS 2032
Figure 47. Europe Rare Disease Pharmaceutical Service Market Share by Country (2021-2032)
Figure 48. Asia-Pacific Rare Disease Pharmaceutical Service Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million)
Figure 49. Asia-Pacific Rare Disease Pharmaceutical Service Market Share by Country: 2021 VS 2025 VS 2032
Figure 50. Asia-Pacific Rare Disease Pharmaceutical Service Market Share by Country (2021-2032)
Figure 51. Latin America Rare Disease Pharmaceutical Service Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million)
Figure 52. Latin America Rare Disease Pharmaceutical Service Market Share by Country: 2021 VS 2025 VS 2032
Figure 53. Latin America Rare Disease Pharmaceutical Service Market Share by Country (2021-2032)
Figure 54. Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million)
Figure 55. Middle East & Africa Rare Disease Pharmaceutical Service Market Share by Country: 2021 VS 2025 VS 2032
Figure 56. Middle East & Africa Rare Disease Pharmaceutical Service Market Share by Country (2021-2032)
Figure 57. Years Considered
Figure 58. Research Process
Figure 59. Key Executives Interviewed
Scope & coverage.
Types
- Drug Discovery
- Clinical Trials
- Others
Applications
- Congenital and Genetic Diseases
- Tumors and Cancer
- Endocrine Diseases
- Others
Companies covered
- Ultragenyx
- Chiesi
- Sciensus
- Abbvie
- Orpharma
- Amgen
- Recordati
- Novartis
- Celgene
- Amryt Pharma
- Johnson & Johnson
- GSK
- Shire
- Merck
- Pfizer
- Biogen
- Sanofi
- AstraZeneca
- Takeda
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Rare Disease Pharmaceutical Service Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Rare Disease Pharmaceutical Service Market Size by Region (2021-2032)
- 1.4.1 Global Rare Disease Pharmaceutical Service Market Size by Region (2021-2026)
- 1.4.2 Global Rare Disease Pharmaceutical Service Market Size by Region (2027-2032)
- 1.5 Key Regions Rare Disease Pharmaceutical Service Market Size (2021-2032)
- 1.5.1 North America Rare Disease Pharmaceutical Service Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Rare Disease Pharmaceutical Service Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Rare Disease Pharmaceutical Service Market Size Growth Rate (2021-2032)
- 1.5.4 South America Rare Disease Pharmaceutical Service Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Rare Disease Pharmaceutical Service Market Size Growth Rate (2021-2032)
2 Rare Disease Pharmaceutical Service Market by Type
- 2.1 Type Introduction
- 2.1.1 Drug Discovery
- 2.1.2 Clinical Trials
- 2.1.3 Others
- 2.2 Global Rare Disease Pharmaceutical Service Market Size by Type
- 2.2.1 Global Rare Disease Pharmaceutical Service Market Size Overview by Type (2021-2032)
- 2.2.2 Global Rare Disease Pharmaceutical Service Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Rare Disease Pharmaceutical Service Market Size Forecasted by Type (2027-2032)
- 2.3 Global Rare Disease Pharmaceutical Service Market Size by Regions
- 2.3.1 North America Rare Disease Pharmaceutical Service Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Rare Disease Pharmaceutical Service Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Rare Disease Pharmaceutical Service Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Rare Disease Pharmaceutical Service Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Rare Disease Pharmaceutical Service Market Size Breakdown by Type (2021-2026)
3 Rare Disease Pharmaceutical Service Market by Application
- 3.1 Type Introduction
- 3.1.1 Congenital and Genetic Diseases
- 3.1.2 Tumors and Cancer
- 3.1.3 Endocrine Diseases
- 3.1.4 Others
- 3.2 Global Rare Disease Pharmaceutical Service Market Size by Application
- 3.2.1 Global Rare Disease Pharmaceutical Service Market Size Overview by Application (2021-2032)
- 3.2.2 Global Rare Disease Pharmaceutical Service Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Rare Disease Pharmaceutical Service Market Size Forecasted by Application (2027-2032)
- 3.3 Global Rare Disease Pharmaceutical Service Market Size by Regions
- 3.3.1 North America Rare Disease Pharmaceutical Service Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Rare Disease Pharmaceutical Service Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Rare Disease Pharmaceutical Service Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Rare Disease Pharmaceutical Service Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Rare Disease Pharmaceutical Service Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Rare Disease Pharmaceutical Service Industry Trends
- 4.2 Rare Disease Pharmaceutical Service Industry Drivers
- 4.3 Rare Disease Pharmaceutical Service Industry Opportunities and Challenges
- 4.4 Rare Disease Pharmaceutical Service Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Rare Disease Pharmaceutical Service Revenue (2021-2026)
- 5.2 Global Rare Disease Pharmaceutical Service Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Rare Disease Pharmaceutical Service Key Company Headquarters & Area Served
- 5.4 Global Rare Disease Pharmaceutical Service Company, Product Type & Application
- 5.5 Global Rare Disease Pharmaceutical Service Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Rare Disease Pharmaceutical Service Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Rare Disease Pharmaceutical Service Players Market Share by Revenue in 2025
- 5.6.3 2025 Rare Disease Pharmaceutical Service Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Ultragenyx
- 6.1.1 Ultragenyx Company Information
- 6.1.2 Ultragenyx Business Overview
- 6.1.3 Ultragenyx Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Ultragenyx Rare Disease Pharmaceutical Service Product Portfolio
- 6.1.5 Ultragenyx Recent Developments
- 6.2 Chiesi
- 6.2.1 Chiesi Company Information
- 6.2.2 Chiesi Business Overview
- 6.2.3 Chiesi Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Chiesi Rare Disease Pharmaceutical Service Product Portfolio
- 6.2.5 Chiesi Recent Developments
- 6.3 Sciensus
- 6.3.1 Sciensus Company Information
- 6.3.2 Sciensus Business Overview
- 6.3.3 Sciensus Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Sciensus Rare Disease Pharmaceutical Service Product Portfolio
- 6.3.5 Sciensus Recent Developments
- 6.4 Abbvie
- 6.4.1 Abbvie Company Information
- 6.4.2 Abbvie Business Overview
- 6.4.3 Abbvie Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Abbvie Rare Disease Pharmaceutical Service Product Portfolio
- 6.4.5 Abbvie Recent Developments
- 6.5 Orpharma
- 6.5.1 Orpharma Company Information
- 6.5.2 Orpharma Business Overview
- 6.5.3 Orpharma Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Orpharma Rare Disease Pharmaceutical Service Product Portfolio
- 6.5.5 Orpharma Recent Developments
- 6.6 Amgen
- 6.6.1 Amgen Company Information
- 6.6.2 Amgen Business Overview
- 6.6.3 Amgen Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Amgen Rare Disease Pharmaceutical Service Product Portfolio
- 6.6.5 Amgen Recent Developments
- 6.7 Recordati
- 6.7.1 Recordati Company Information
- 6.7.2 Recordati Business Overview
- 6.7.3 Recordati Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Recordati Rare Disease Pharmaceutical Service Product Portfolio
- 6.7.5 Recordati Recent Developments
- 6.8 Novartis
- 6.8.1 Novartis Company Information
- 6.8.2 Novartis Business Overview
- 6.8.3 Novartis Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Novartis Rare Disease Pharmaceutical Service Product Portfolio
- 6.8.5 Novartis Recent Developments
- 6.9 Celgene
- 6.9.1 Celgene Company Information
- 6.9.2 Celgene Business Overview
- 6.9.3 Celgene Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Celgene Rare Disease Pharmaceutical Service Product Portfolio
- 6.9.5 Celgene Recent Developments
- 6.10 Amryt Pharma
- 6.10.1 Amryt Pharma Company Information
- 6.10.2 Amryt Pharma Business Overview
- 6.10.3 Amryt Pharma Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Amryt Pharma Rare Disease Pharmaceutical Service Product Portfolio
- 6.10.5 Amryt Pharma Recent Developments
- 6.11 Johnson & Johnson
- 6.11.1 Johnson & Johnson Company Information
- 6.11.2 Johnson & Johnson Business Overview
- 6.11.3 Johnson & Johnson Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Johnson & Johnson Rare Disease Pharmaceutical Service Product Portfolio
- 6.11.5 Johnson & Johnson Recent Developments
- 6.12 GSK
- 6.12.1 GSK Company Information
- 6.12.2 GSK Business Overview
- 6.12.3 GSK Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 GSK Rare Disease Pharmaceutical Service Product Portfolio
- 6.12.5 GSK Recent Developments
- 6.13 Shire
- 6.13.1 Shire Company Information
- 6.13.2 Shire Business Overview
- 6.13.3 Shire Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Shire Rare Disease Pharmaceutical Service Product Portfolio
- 6.13.5 Shire Recent Developments
- 6.14 Merck
- 6.14.1 Merck Company Information
- 6.14.2 Merck Business Overview
- 6.14.3 Merck Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Merck Rare Disease Pharmaceutical Service Product Portfolio
- 6.14.5 Merck Recent Developments
- 6.15 Pfizer
- 6.15.1 Pfizer Company Information
- 6.15.2 Pfizer Business Overview
- 6.15.3 Pfizer Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Pfizer Rare Disease Pharmaceutical Service Product Portfolio
- 6.15.5 Pfizer Recent Developments
- 6.16 Biogen
- 6.16.1 Biogen Company Information
- 6.16.2 Biogen Business Overview
- 6.16.3 Biogen Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.16.4 Biogen Rare Disease Pharmaceutical Service Product Portfolio
- 6.16.5 Biogen Recent Developments
- 6.17 Sanofi
- 6.17.1 Sanofi Company Information
- 6.17.2 Sanofi Business Overview
- 6.17.3 Sanofi Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.17.4 Sanofi Rare Disease Pharmaceutical Service Product Portfolio
- 6.17.5 Sanofi Recent Developments
- 6.18 AstraZeneca
- 6.18.1 AstraZeneca Company Information
- 6.18.2 AstraZeneca Business Overview
- 6.18.3 AstraZeneca Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.18.4 AstraZeneca Rare Disease Pharmaceutical Service Product Portfolio
- 6.18.5 AstraZeneca Recent Developments
- 6.19 Takeda
- 6.19.1 Takeda Company Information
- 6.19.2 Takeda Business Overview
- 6.19.3 Takeda Rare Disease Pharmaceutical Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.19.4 Takeda Rare Disease Pharmaceutical Service Product Portfolio
- 6.19.5 Takeda Recent Developments
7 North America
- 7.1 North America Rare Disease Pharmaceutical Service Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Rare Disease Pharmaceutical Service Market Size by Country (2021-2026)
- 7.3 North America Rare Disease Pharmaceutical Service Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Rare Disease Pharmaceutical Service Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Rare Disease Pharmaceutical Service Market Size by Country (2021-2026)
- 8.3 Europe Rare Disease Pharmaceutical Service Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Rare Disease Pharmaceutical Service Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Rare Disease Pharmaceutical Service Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Rare Disease Pharmaceutical Service Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Rare Disease Pharmaceutical Service Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Rare Disease Pharmaceutical Service Market Size by Country (2021-2026)
- 10.3 South America Rare Disease Pharmaceutical Service Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Rare Disease Pharmaceutical Service Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Rare Disease Pharmaceutical Service Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,450USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst